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SUMMARY : Immunohistochemical study was performed on expressions of c-myc, 
c-fos and CA19-9 in gallbladder tissue with or without malignant lesions. A total of 81 
tissues were divided into four groups including 47 carcinomas, 3 dysplasias, 17 metaplasias 
and 14 normal lesions. After these tissues were routinely fixed in 10% formalin solution 
and embedded in paraffin, 4 micrometer-thick sections were made and stained with 
hematoxylin-eosin to classify the type of lesions. Immunohistochemical stains were carried 
out for c-myc and c-fos oncoproteins, and CA19-9. The percentages of positive reaction 
for c-myc oncoprotein were 77%, 67%, 88% and 36%, those for c-fos oncoprotein were 83%, 
66%, 35% and 7%, and those for CA19-9 were 85%, 100%, 88% and 71% in carcinoma, dysplasia, 
metaplasia and normal tissues, respectively. These results suggest that c-myc and c-fos 
oncogenes play some kind of roles in malignant transformation of the gallbladder tissues 
and that abnormal expression of CA19-9 is the sign of antigen reversion of carcinoma 
cells toward embryonic cells of the gallbladder tissue.
       INTRODUCTION 
 Recent investigators have indicated that 
protooncogenes have crucial roles in normal cell 
proliferation and differentiation as well as in 
the development and progression of various 
tumors (2, 4, 21, 22). C-myc gene has been re-
ported to be amplified and overexpressed in 
various human cancers such as uterine cancer 
(18), hematopoietic malignancies (19), colonic 
carcinoma (6), and thyroid carcinoma (24). C-fos 
gene has also been reported to be expressed in 
verious types of cells and tissues at different 
developmental stages (7) and in a small number 
of human cancers (14, 15). CA19-9 (carbohydrate 
antigen 19-9) is one of the useful tumor markers
of the gastrointestinal tract which was originally 
developed by Koprowsski et al. (13) in 1979. 
Several authors (1, 12, 20) have reported that 
serum level of CA19-9 is high in case of 
gallbladder carcinoma. From theses considera-
tion, we analyzed the expression of c-myc and 
c-fos oncogene products and CA19-9 in the 
gallbladder carcinoma tissues in order to obtain 
better understanding of roles of oncogenes and 
tumor marker in carcinogenesis of the gall-
bladder.
   MATERIALS AND METHODS 
 Tissues specimens were obtained from a total 
of 81 cholecystectomized cases including 14 
normal controls (N), 17 metaplasias (M), 3
Fig. 1. Comparison of intensity of immunohistochemical reaction (Moderately differentiated 
       adenocarcinoma) 
      A : Definitely positive (+++) ; Positive reaction is noted in both nuclei and cytoplasm 
         of more than 75% of carcinoma cells (c-fos X 100). 
      B : Moderately positive (+ +) ; Positive reaction is noted in nuclei of 50% of carcinoma 
        cells (c-fos X 100). 
      C : Weaky positive (+) ; Positive reaction is noted in the nuclei of less than 25% of 
         carcinoma cells (c-myc X 100). 
      D : Negative (-) ; No significant reaction is noted (c-fos X 100)
dysplasias (D), and 47 carcinomas (C). Tissues 
were immediately fixed in 10% formalin solution. 
Sections embedded in paraffin were cut into 4 
micrometer thickness and stained with hemato-
xylin-eosin (HE). In addition to the conventional 
histological staining, expressions of the c-myc 
and c-fos oncogene products, and the CA19-9 
were immunohistoshemically examined. The pri-
mary antibody of c-myc (Oncor), c-fos oncogene 
product (Cembridge Research) and that of 
CA19-9 (Oris) were purchased. Immunoper-
oxidase staining was performed on sectioned 
tissues by the peroxidase-antiperoxidase (PAP) 
method of Sternberger et al. (23). Secions were 
treated with 0.3% hydrogen peroxide to block 
endogenous peroxidase. After exposure to non-
immune serum, the sections were reacted with 
either the primary anti-sera or non-immune 
sera, link antibodies, followed by peroxidase-
anti-peroxidase complex for one hour at room 
temperature. The sections were then washed 
three times with 0.1 M phosphate buffered
Fig. 2. Immunostaining pattern of CA19-9 
      A : Apical type ; Positive reaction is limited to luminal surface of the epithelium 
       (x 100). 
      B : Cytoplasmic type, with polarity ; Positive reaction is noted in supranuclear and 
         luminal surface area (x 100). 
      C : Cytoplasmic type without polarity ; Postive reaction is noted in entire cytoplasm and 
        cytoplasmic membrane (X50). 
      D : Stromal type ; Positive reaction is noted in stromal cells (x 100).
solution (PH 7.5) for 5 minutes after each 
antibody applications and were treated with 
diaminobenzidine in hydrogene peroxide. The 
intensity of immunoreaction of c-myc and c-
fos oncogene products was evaluated by light 
microscope at the magnification of 100 times. 
And the following 4 gradings of intensity of 
immunoreaction were adopted : More than 50% 
of positive tumor cells, (+++); 25% to 50% of 
positive tumor cells, (++); less than 25% of 
positive tumor cells, (+) ; no positive cells (-)
(Fig. 1). For the evaluation of immuno-
histochemical ataining pattern of CA19-9, 
Hamada's criteria (9) was applied as follows : 
1) Only luminal cytoplasmic surface is positively 
atained(Apical type), 2) Supranuclear portion of 
the cytoplasm is intensely stained (Cytoplasmic 
type, with polarity), 3) Total area of the 
cytoplasm is positively atained (Cytoplasmic 
type, without polarity), 4) Surrounding stromal 
cells are positively stained (Stromal type) (Fig. 
2).
Fig. 3. Immunohistochemistry of c-myc gene product 
      A : Definitely positive reaction is noted in both nuclei and cytoplasm of carcinoma cells 
       (x100) 
      B : Moderate positive reaction is noted especially in nuclei of the metaplastic epithelium 
       (x 50). 
      C : Slight positive reaction is noted in nuclei of the normal epithelium (x 50).
            RESULTS 
     Intense positive reaction of c-myc gene 
   product was seen in both nuclei and the cyto-
   plasm of carcinoma cells. However, slight to 
   moderate positive reaction of c-myc gene was
   observed especially in the unclei of the non-
   carcinomatous cells (Fig. 3). Table 1 indicates 
   frequency of the c-myc positive cells in C, D, 
   M. and N groups. Positive rates of c-myc gene 
   product was 77%, 67%, 88%, and 36% in C, D, M, 
   and N groups, respectively. Furthermore, 11 out
of 47 carcinoma cases (23%) showed intense 
definitely positive reaction of c-myc oncogene 
product. Fig. 4 shows immunohistochemical 
findings of c-fos oncogene product in various 
types of gallbladder lesions and immuno-
histochemical staining pattern of those were 
similar to those of c-myc gene product. Positive 
rates of c-fos oncogene product in various types 
of gallbladder lesions are listed in Table 2. 
Positive rates of c-fos oncogene product were 83%, 
66%, 35%, and 7% in C, D, M, and N groups, 
respectively. Definitely positive reaction of c-fos 
oncogene product was obsetved in 9 out of 47
Fig. 4. Immunohistochemistry of c-fos gene product 
      A : Definitely positive reaction is noted in both nuclei and cytoplasm of carcinoma cells 
       (x 100). 
      B : Moderate positive reaction is noted especially in nuclei of the metaplastic epithelium 
       (x50). 
      C : Slight positive reaction is noted in nuclei of the normal epithelium (x 20).
Table 1, Immunohistchemical postive rate of c-myc 
        gene product in gallbladder tissues of each 
         group
Table 2. Immunohistochemical positive rate of 
        c-fos gene product in gallbladder tissues of
         each group
Fig. 5. Immunohistochemistry of CA19-9 
      A : Positive reaction is noted in glandular epithelium of carcinoma (x 100) 
      B : Positive reaction is noted in mucosal epithelium of the gallbladder with gland 
        metaplasia (X50). 
      C : Positive reaction is occasionally noted in nuclei of the normal mucosal epithelium 
       (x 100).
carcinoma cases (19%). As for immunohisto-
chemical staining pattern, numerous cases of 
carcinomas presented cytoplasmic without 
polarity type. Apical and cytoplasmic with 
polarity types of immunohistochemical stain-
ing patterns were frequently seen in non-
carcinomatous gallbladder tissues (Fig. 5). 
Positive rates of CA19-9 in each group are listed 
in Table 3. Positive rates of CA19-9 were 85%, 
100%, 88%, and 71% in C, D, M, and N groups, 
respectively. Table 4 indicates immunohisto-
chemical staining pattern of CA19-9 in each 
group. Stromal type was frequently seen in
Table 3. Immunohistchemical positive rate of 
        CA19-9 in gallbladder tissues of each 
         group
           - + ++ +-H- Total 
N 4 1 8 1 14  group (29%) (7%) (52%) (7%) (100%) 
M group 2 6 8 1 17       (1 %) (35%) (47%) ( 6%) (100%) 
D group (0%) (33%) (67%) (0%) (99%) 
C group 7 16 19 5 47       (15%) (34%) (40%) (11%) (100%)
Table 4. Frequency of various type of immuno-
        histochemical localization of CA19-9 in 
        gallbladder tissues of each group
        Apical With Wiout Stromal -total 
        type type type type 
N group 0 15 0 0 10       ( %) (100%) ( 0%) ( %) (100%)
M 0 11 4 01 15  group (0%) (73%) (27%) (0%) (100%) 
D group (0%) (33%) (67%) (0%) (100%) 
C group 0 14 18 8 40       ( %) (35%) (45%) (20%) (10 %)
With type ; Cytoplasmic type, with polarity 
Without type ; Cytoplasmic type, without polarity
Group C (20%), and cytoplasmic type with 
polarity was prevalently observed in Groups M 
(73%) and N (100%).
         DISCUSSION 
  Various mitogens induce the c-myc gene (3, 
11), expression of which is related to the 
transition from Go to G1 of the cell cycle (17). 
It has been reported that induction of c-fos gene 
and protein by browth factors precedes acti-
vation of c-myc (16). Therefore, immunoreaction 
of c-myc and c-fos gene products was expected 
in the nuclei of the proliferationg or differ-
entiating cells in the gallbladder tissues. This 
hypothesis was confirmed by the present 
findings that c-myc and c-fos oncogene 
products were occasionally seen in nuclei of the 
cells in the gallbladder tissues. the present data 
also demonstrated more abundant c-myc and 
c-fos oncogene product in malignant lesions 
than in non-malignant lesions and normal 
tissues of the gallbladder. In situ hybridization 
study also demonstrated significant amount of 
c-myc and c-fos messenger RNA especially in 
malignant lesions of the gallbladder (10). 
Furthermore, these gene products were also seen 
in the entire area of the cytoplasm as well as 
nuclei of malignant cells suggesting deteriorated 
regulatory role of cell proliferation and 
differentiation of c-myc and c-fos in malignant 
cells. Futher studies are required to elucidate 
whether overexpression of c-myc and c-fos is
the primary or secondary event of carcino-
genesis of the gallbladder. 
 Higher serum level of CA19-9 is well docu-
mented in cancer cases of gastrointestinal and 
biliary tracts (5,8). It has been reported that 
immunohistochemical positive rete of CA19-9 
was more than 70% (1, 12, 20). In accordance with 
results of these studies, immunohistochemical 
positive rate of CA19-9 in carcinoma tissues of 
our cases was 85%. As for immunohistochemical 
staining pattern of CA19-9, most carcinoma 
cases displayed cytoplasmic type without 
polarity. However, no significant staining 
reaction of CA19-9 was detected in 7 out of 47 
carcinoma cases. This discrepancy of the 
results could be ascribed to several factors such 
as technical failure and sialosylated Lewisa 
antigen-related epitope of CA19-9. In normal 
cases, immunohistochemical positive rate of 
CA19-9 was 71% but immunohistochemical 
staining pattern was exclusively cytoplasmic 
type with polarity. Thus, CA19-9 was pro-
dominantly restricted to the apical surface in 
non-malignant lesions, and was distributed over 
the entire cell surface in malignant lesions. 
These abnormalities in cell surface expression 
of CA19-9 suggest the antigen reversion of 
carcinoma cells toward embryonic cells in 
carcinogenesis. Further studies are required to 
examine the relationship between expression of 
oncogenes and antigen reversion.
         REFERENCES 
1) Ariyoshi, Y., Kuwahara, M., Akatuka, H., and 
   Kitou, K.: CA19-9 as a new diagnostic tool for 
   disease of the liver, biliary tract and pancreas. 
  KANTANS UI 11 : 525-531 (1985). 
2) Alitao, K., Schwab, M., Lin, C. C., Varmus, H. 
   and Bishop, J. M.: Homogeneously staining
   chromosomal regions contain amplified copies 
   of an abundantly expressed cellular oncogene 
   (c-myc) in malignant neuroendocrine cells from 
   a human colon carcinoma. Proc Natl Acad Sci 
  USA 80:1707-1711 (1983). 
3) Armelin, H. A., Armelin, M. C. S., Kellym, K., 
   Stewart, T., Leder, P., Cochran, B. H. and Stiles, 
   C. D.: Functional role for c-myc in the mitogenic 
   response to platelet-derived growth factor. 
  Nature 310: 655-660 (1984).
4) Collin, S. and Groudine, M.: Amplification of 
   endogenous myc-related DNA sequences in a 
   human myeloid leukaemia cell line. Nature
  298:679--681 (1982). 
5) Del Villano, B. C., Brennan, S., Brock, P., Bucher, 
   C., Liu, V., McClure, M., Rake, B., Spase S., 
   Westrick, B., Schoemaker, H. and Zurawski, V. 
   R. J : Radioimmunometric assay for a mono-
   clonal antibody-defined tumor marker, CA19-9. 
  Clin Chem 29:549-552 (1983). 
6) Erisman, M. D., Rothberg, P. G., Diehl, R. E., 
   Morse, C. C., Spandorfer, J. M., and Astrin, S. M.: 
   Deregulation of c-myc gene expression in human 
   colon carcinoma is not accompanied by 
   amplification or rearrangement of the genes. Mol 
  Cell Biol 5:1969-1976 (1985). 
7) Gonda, T. J. and Metcale, D.: Expression of myb, 
   myc and fos proto-oncogenes during the 
   differentiation of a murine myeloid leukaemis. 
  Nature 310:249-251 (1984). 
8) Gupta, M. K., Arciaga, R., Bocci, L., Tubbs, R., 
   Bukowski, R, and Deodhar, S. D.: Measurement
   of a monoclonal-antibodydefined antigen (CA19-9) 
   in the sera of patient with malignant and 
   nonmalignant diseases. Comparison with 
   carcinoembryonic antigen. Cancer 56:277-283 
  (1985). 
9) Hamada, Y., Yamamura, M., Hioki, K., 
   Yamamoto M., Nagura, H., and Watanabe, K.: 
   Immunohistochemical study of carcino-
   embryonic antigen levels. Cancer 55:136-141 
  (1985). 
10) Hamada, Y., Toda, T., Nagamine, M., Miura, M., 
   and Sugamata, M.: In situ hybridization study 
   of c-myc bene in non-malignant and malignant 
   thyroid tissues. J Med Soc Toho, Japan (in press). 
11) Kelly, K., Cochran, B. H., Stiles, C. D., and Leder, 
   P.: Cell-specific regulation of the c-myc gene by 
   lymphocyte mitogens and plateletderived
  growth factor. Cell 35:603-610 (1983). 
12) Kishimoto, H. and Futamura, Y.: Immuno-
  histochemical study of CEA and CA19-9 in 
   biliary tract epithelium. Jpn J Gastroenterol
  83:2402-2410 (1986). 
13) Koprowski, H., Steplewski, Z., Mitchell, K., 
   Herlyn, M., Herlyn, D. and Fuhrer, P.: Colorectal
   carcinoma antigens detected by hybridoma 
   antibodies. Somatic Cell Genet 5 : 957-971 (1979). 
14) Lehn, P., Sigaux, F., Grausz, D., Loiseau, P., 
   Castaigne, S., Degos, L., Flandrin, G., and Daury, 
   F.: C-myc and c-fos exression dyring interferon 
   alpha therapy of hairy cell leukemia. Blood 68: 
  967-970 (1986).
15) Mavilio, F., Sposi, N. M., Petrini, M., Bottero, L., 
   Marinucci, M., De Rossi, G., Amadori, S., 
   Mandelli, F. and Peschle, C.: Expression of 
   cellular oncogenes in primary cells from human
   acute leukemias. Proc Natl Acad Sci USA 83: 
  4394-4398 (1986). 
16) Muller, R., Bravo, R., and Burckhardt, J.: 
   Induction of c-fos gene and protein by growth
   factors precedes activation of c-myc. Nature 
  312:716-720 (1984). 
17) Rabbitts, P. H., Watson, J. V., Lamond, A., 
   Foster, A., Stinson, N. A., Evan, G., Fischer, W., 
   Atherton, E., Sheppar D, R. and Rabbitts, T. H.: 
   Metabolism of c-myc gene products ; c-myc 
   mRNA and protein expression in the cell cycle. 
  EMBO J 4 : 2009-2015 (1985). 
18) Riou, G., Le, M. G., Le Doussal, V., Barrois, M., 
   George, M., and Hale, C.: C-myc proto-oncogene 
   expression and prognosis in early carcinoma of 
   the uterine cervix. Lancet, i, 761-763 (1987). 
19) Rothberg, P. G., Erisman, M. D., Diehl, R. E., 
   Rovigatti, U. G., and Astin S. M.: Structure and 
   expression of the oncogene c-myc in fresh tumor 
   material from patients with hematopoietic 
  malignancies. Mol Cell Biol 4:1096-1103 (1984). 
20) Sasaki, R.: Immunohistochemical study of 
   cancerassociated carbohydrate antigens in 
   carcinoma of the billiary tract. J. Jpn Surg Soc 
  90:1976-1988 (1988). 
21) Shibuya, M., Yokota, J. and Uehara, Y.: Ampli-
   fication and expression of cellular oncogene 
   (c-myc) in human gastric adenocarcinoma cells. 
  Mol cell Biol 5:414-419 (1985). 
22) Slamon, D. J., De Kernion, J. B., Verma, I. M., and 
   Cline, M. J.: Expression of cellular oncogenes in 
   human malignancies. Science 224: 256-262 (1984). 
23) Sternberger, L. A., Hardy, P. H., JR., Cuculis, J. 
   J. and Howard, G. M.: The unlabeled antibody
   enzyme method of immunohistochemistry. Pre-
   paration and properties of soluble antigen-
   antibody complex (Horseradisy peroxidase-
   antihorsetadisy perocidase) and its use in 
   identification of spiroshetes. J Histochem
  Cytochem 18: 314-333 (1970). 
24) Yamashita, S., Ong, J., Fagin, J.A., and Melmed, 
   S.: Expression of the myc cellular proto-
   oncogene in human thyroid tissue. J Clin 
  Endocrinol Metab 63: 1170-1173 (1986).
